Form 4: 4D Molecular Therapeutics Executive Acquires Stock Options
SEC Form 4 Filing
Scott Bizily, Chief Legal Officer of 4D Molecular Therapeutics, acquired stock options for 78,500 shares at an exercise price of $4.14 on March 6, 2025.
Summary
- On March 6, 2025, Scott Bizily, the Chief Legal Officer of 4D Molecular Therapeutics, acquired stock options.
- The options grant the right to buy 78,500 shares of common stock at an exercise price of $4.14 per share.
- The options vest monthly, starting on March 6, 2025, with full vesting occurring on the fourth anniversary.
- The expiration date for the options is March 5, 2035.
Sentiment
Score: 5
Explanation: This is a neutral event, reflecting standard executive compensation practices.
Industry Context
This filing is a routine disclosure of stock option grants to a company executive, which is a common practice in the biotechnology industry to incentivize and retain key personnel.
Stakeholder Impact
- The stock option grant may incentivize the Chief Legal Officer to contribute to the company's long-term success, potentially benefiting shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/06/2025 | Date of earliest transaction and Vesting Commencement Date |
| 03/05/2035 | Expiration date of the stock options |
| 03/10/2025 | Date of signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.